To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose-lowering drugs.In this exploratory analysis of LixiLan-L (N = 736), efficacy outcomes were assessed within population subgroups derived from the following baseline characteristics: glycated haemoglobin [HbA1c; <8

作者：Carol, Wysham；Riccardo C, Bonadonna；Vanita R, Aroda；Manuel, Puig Domingo；Christoph, Kapitza；William, Stager；Christine, Yu；Elisabeth, Niemoeller；Elisabeth, Souhami；Richard M, Bergenstal

来源：Diabetes, obesity & metabolism 2017 年